OH-GE-CURRENT
27.9.2021 20:08:12 CEST | Business Wire | Press release
GE Current, a Daintree company, today introduced the next generation of the Arize Element L1000, a top light for commercial greenhouses and indoor farms. The next generation features three models with expanded spectral options, a high photon flux of up to 2,350 μmol/s, high efficacy levels of up to 3.6 µmol/J and is proudly assembled in the heart of Appalachia.
“We set out to engineer the world’s most rugged and durable light fixture for commercial agriculture, thanks to our 20-plus years of LED fixture design experience combined with over 65 years of manufacturing excellence and scale in Hendersonville, North Carolina,” said Mike Doss, Current’s VP of Specialty. “We’ve improved the Element in every possible way, from light intensity to efficacy, and now it is proudly assembled in the Appalachians.”
The Element family now features eight spectral options in three all-new models:
- L1000: The L1000 is a flexible, all-purpose fixture, with a PPF of up to 1900 µmol/s at 3.3 µmol/J.
- L1000 HE: The L1000 HE (high efficiency) emits 1900 µmol/s at 3.6 µmol/J, for large-scale commercial greenhouses.
- L1000 HO: The L1000 HO (high output) offers the best of both worlds: PPF levels of up to 2350 µmol/s at 3.4 µmol/J.
The Element family features Current’s proprietary XW Optic, which precisely targets light dispersion, resulting in wider coverage in low headspace applications. It reduces the number of fixtures needed by 10 to 15% without sacrificing uniformity or crop quality, lowering capital investment. The mounting options have also been simplified, with the fixture and power supply sharing common mounting hardware.
Powering Opportunities in Appalachia
Proudly assembled in Hendersonville, North Carolina, the new Arize Element L1000 has been selected by AppHarvest (NASDAQ: APPH) for its new Morehead, Kentucky, farm, slated to open later this year.
“As a grower, we have to consider several factors to maximize crop production and yield. One factor we pay close attention to is the management of light,” said Jose “Pepe” Calderon, Head Grower, AppHarvest. “With the Current LED grow lights, we have found several advantages such as dimmable intensities and energy efficiency, giving us the benefits for higher production, plant development, earlier crops, better climate control and energy savings.”
Learn more about Current’s newest top lighting solution at www.gecurrent.com/horticulture .
About GE Current, a Daintree company:
Current enhances commercial, industrial, city and specialty applications with advanced lighting and intelligent controls. Working with our partners, we deliver the best possible outcomes for our customers. See why Current is always on at www.gecurrent.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005730/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom